GSK-114

GSK-114 is a highly selective, orally active TNNI3K inhibitor (IC50= 25 nM) . GSK-114 shows a 40-fold selectivity for TNNI3K over B-Raf kinase (IC50= 1 μM) . Cardiac troponin I-interacting kinase (TNNI3K or CARK) is a member of the tyrosine-like kinase family that is selectively expressed in heart tissue[1].

Product Specifications

CAS Number

[1301761-96-5]

Product Name Alternative

(Z)-Mutagenic Impurity of Tenofovir Disoproxil,BMS-387032,Mutagenic Impurity of Tenofovir Disoproxil (Standard); Tenofovir Impurity 2 (Standard)

UNSPSC

12352005

Hazard Statement

H315, H319

Target

MAP3K

Type

Reference compound

Related Pathways

MAPK/ERK Pathway

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/gsk-114.html

Purity

99.52

Solubility

DMSO : 5.95 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=S(NC)(C1=CC=C(N(C)C)C(NC2=C3C=C(OC)C(OC)=CC3=NC=N2)=C1)=O

Molecular Formula

C19H23N5O4S

Molecular Weight

417.48

Precautions

H315, H319

References & Citations

[1]Lawhorn BG, et al. GSK114: A selective inhibitor for elucidating the biological role of TNNI3K. Bioorg Med Chem Lett. 2016;26 (14) :3355-3358. |[2]Asquith CRM, et al. New Insights into 4-Anilinoquinazolines as Inhibitors of Cardiac Troponin I-Interacting Kinase (TNNi3K) . Molecules. 2020;25 (7) :1697. Published 2020 Apr 7.